All News
RISK OF NON-MELANOMA SKIN CANCER WITH TNFi AND OTHER bDMARDs IN PATIENTS WITH PSORIATIC ARTHRITIS: A SWEDISH AND DANISH COHORT STUDY- despite having minimal sun 25% increase NMSC TNFis vs other bDMARDs - skin checks ! @RheumNow #EULAR2024
Peter Nash drpnash ( View Tweet)
EULAR Abstract Archive
OP0031 (2024)
COMPARATIVE ANALYSIS OF TNF INHIBITORS & IL17 INHIBITORS IN PSORIATIC ARTHRITIS: CARDIOVASCULAR OUTCOMES signif absolute risk diff 3 % ischaemic heart disease 2 % heart failure TNFi vs IL17i https://t.co/fNIiMt4caL. @RheumNow #EULAR2024
Links:
Peter Nash drpnash ( View Tweet)
Points to consider in pregnancy in
#rheumatic diseases
3 points
✅TNFi all OK 👍
? Only if you can’t control disease use other #bDMARDs
Baby #vaccinations if exposed to #biologics while present
#rotovirus ok
other live vaccines >6 mos
#EULAR2024 @eular_org @RheumNow https://t.co/MyJdA7p7zh
Janet Pope Janetbirdope ( View Tweet)
500+ pts AxSPA
No difference in drug discontinuation between IL-17i, TNFi, IL23i over time
Adjusted for CRP, co-medication w/ MTX + classic covariates
IL-17i and IL-23i had experienced a higher number bDMARD failures
#EULAR2024 POS0259 @RheumNow https://t.co/F3B6uXyAca
Aurelie Najm AurelieRheumo ( View Tweet)
Cohort from Netherlands 400+ PsA pts IR first bioDMARD
300+ switched TNFi->IL-17i, 99 cycled TNFi->TNFi
3year retention rates
12 mo 75% cyclers 80% swappers
24mo 60% cyclers 56% swappers
No difference in treatment failure or DAS28 CRP
#EULAR2024 @RheumNow POS0278 https://t.co/J8ONjVAFqG
Aurelie Najm AurelieRheumo ( View Tweet)
more evidence in PsA - switch MOA rather than cycle within class failed first TNF @RheumNow #EULAR2024 https://t.co/hf2UB5MXEy
Peter Nash drpnash ( View Tweet)
important session worth reading the full recommendations - TNF tick of approval @RheumNow #EULAR2024 https://t.co/ORDocVie11
Peter Nash drpnash ( View Tweet)
#opportunistic inf in #autoimmune dz
🎤 @khyrich
👉#herpes zost is ⬆️⬆️,esp😳#lupus (💉 >18yo🇺🇸)
👉#HBV react ⬆️⬆️ w/ RTX (9.1%) >>TNFi, JAKi, IL-6
👉 🙅♂️ #TB repeat 🧪 on #DMARD if 🚫new risk fact/gap⚠️
🔗#eular 2022 guide:
https://t.co/PIpGpTrH28
#eular2024
#rheumx
@RheumNow https://t.co/kouXvradiC
Artem Minalyan, MD, DABOM AMinalyan ( View Tweet)
#opportunistic inf in #autoimmune dz
🎤 @khyrich
👉#herpes zost is ⬆️⬆️,esp😳#lupus (💉 >18yo🇺🇸)
👉#HBV react ⬆️⬆️ w/ RTX (9.1%) >>TNFi, JAKi, IL-6
👉 🙅♂️ #TB repeat 🧪 on #DMARD if 🚫new risk fact/gap⚠️
🔗#eular 2022 guide:
https://t.co/PIpGpTrH28
#eular2024
#rheumx
@RheumNow https://t.co/kouXvradiC
Artem Minalyan, MD, DABOM AMinalyan ( View Tweet)
Cycle or swap 2? Post failure to a first TNFi in patients with PsA, there was no difference in cycle versus swap to IL17i for drug retention rate or disease activity. In male PsA patients a cycle strategy had a longer drug retention rate compared to a swap (IL-17i) strategy.… https://t.co/5BykvDwFWV https://t.co/GfcnIltV2A
Dr. Antoni Chan synovialjoints ( View Tweet)
Cycle or swap 2? Post failure to a first TNFi in patients with PsA, there was no difference in cycle versus swap to IL17i for drug retention rate or disease activity. In male PsA patients a cycle strategy had a longer drug retention rate compared to a swap (IL-17i) strategy.… https://t.co/5BykvDwFWV https://t.co/GfcnIltV2A
Dr. Antoni Chan synovialjoints ( View Tweet)
What is better in #PsA
#psoriatic #arthritis
#TNFi or #apremilast #PDE4i
#COREVITAS database study in #PsA
YOU can guess the answer!
1st line advanced RxTNFi lasts longer - retention
Vs PDE4i
#EULAR2024 @RheumNow @eular_org
POS0990 https://t.co/VmYG6Rj87c
Janet Pope Janetbirdope ( View Tweet)
Cycle or Swap? The swap strategy (SG) (i.e. from TNFi to IL17i) had higher retention rates compared to the change strategy (CG) choice in PsA patients who failed the first line of advanced treatment. The 5 years retention rate in SG was higher than in CG (57,8% vs 45,2%; p=0.1).… https://t.co/pH5rFI00vK https://t.co/XqTHO1tIr3
Dr. Antoni Chan synovialjoints ( View Tweet)
Cycle or Swap? The swap strategy (SG) (i.e. from TNFi to IL17i) had higher retention rates compared to the change strategy (CG) choice in PsA patients who failed the first line of advanced treatment. The 5 years retention rate in SG was higher than in CG (57,8% vs 45,2%; p=0.1).… https://t.co/pH5rFI00vK https://t.co/XqTHO1tIr3
Dr. Antoni Chan synovialjoints ( View Tweet)
The age old question in #inflammatory #arthritis
Should you cycle within TNFi class or move on to another MOA in
#PsA #psoriatic #arthritis
Better retention to go to a IL17i vs another TNFi in observational study comparing the 2
POS0266
#EULAR2024 @RheumNow @eular_org https://t.co/CXcmYAG4m9
Janet Pope Janetbirdope ( View Tweet)
Can you predict which pts with
#PsA
#psoriatic #arthritis
Will respond to #TNFi #Rx?
Well, 🤔 maybe
Needs validation and an easy reliable inexpensive biomarker!
#EULAR2024 @RheumNow @eular_org
POS0992 https://t.co/Ce92561AMO
Janet Pope Janetbirdope ( View Tweet)
EULAR 2024 – Day 2 Report (A Difficult RA Day)
Day 2 at EULAR 2024 was a big poster day for many with several good sessions and oral presentations on Preventing RA, new vasculitis therapies and a session devoted to the 50th anniversary of the Moll & Wright Criteria.
Read Article
Swedish/Danish cohort study in PsA
17000+ bionaïve 8000+ TNFi & 2000+ other MoA
Overall non melanoma skin cancer rate 651
(505 BCC & 87 SCC)
TNFi treated pts:
HR 1.25 NMSC vs. bionaive (95CI 1.04 to 1.50)
HR 1.19 NMSC vs. other MoA (ns)
#EULAR2024 @RheumNow AbstOP0150 https://t.co/DVj8l7yFR6
Aurelie Najm AurelieRheumo ( View Tweet)
OP0137 is comparative analysis of clinical efficacy & drug retention of b/tsDMARDs
>1/2 D2T RA pts starting JAKi, RTX, IL-6Ri, or TNFi, but ~1/3 w abatacept, achieved remission or low disease activity in 6m & maintained consistent drug retention for 2yrs
@RheumNow #EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
In a Swedish-Danish cohort study on patients with PsA, treatment with TNFi was associated with a small increased risk of NMSC and with non-significant numeric risk increases for both BCC and SCC compared with bDMARD naïve #EULAR2024 Abstract 0150 @RheumNow https://t.co/vC4pgSKmfY
Dr. Antoni Chan synovialjoints ( View Tweet)